JP2003514910A5 - - Google Patents

Download PDF

Info

Publication number
JP2003514910A5
JP2003514910A5 JP2001540095A JP2001540095A JP2003514910A5 JP 2003514910 A5 JP2003514910 A5 JP 2003514910A5 JP 2001540095 A JP2001540095 A JP 2001540095A JP 2001540095 A JP2001540095 A JP 2001540095A JP 2003514910 A5 JP2003514910 A5 JP 2003514910A5
Authority
JP
Japan
Prior art keywords
hydroxy
dihydro
carbonyl
amino
trifluoroethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001540095A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003514910A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/032089 external-priority patent/WO2001038332A1/en
Publication of JP2003514910A publication Critical patent/JP2003514910A/ja
Publication of JP2003514910A5 publication Critical patent/JP2003514910A5/ja
Withdrawn legal-status Critical Current

Links

JP2001540095A 1999-11-24 2000-11-21 Hivプロテアーゼ阻害剤としてのガンマ−ヒドロキシ−2−(フルオロアルキルアミノカルボニル)−1−ピペラジンペンタンアミド類 Withdrawn JP2003514910A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16747899P 1999-11-24 1999-11-24
US60/167,478 1999-11-24
US17705300P 2000-01-20 2000-01-20
US60/177,053 2000-01-20
PCT/US2000/032089 WO2001038332A1 (en) 1999-11-24 2000-11-21 Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides as hiv protease inhibitors

Publications (2)

Publication Number Publication Date
JP2003514910A JP2003514910A (ja) 2003-04-22
JP2003514910A5 true JP2003514910A5 (enExample) 2008-01-17

Family

ID=26863215

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001540095A Withdrawn JP2003514910A (ja) 1999-11-24 2000-11-21 Hivプロテアーゼ阻害剤としてのガンマ−ヒドロキシ−2−(フルオロアルキルアミノカルボニル)−1−ピペラジンペンタンアミド類

Country Status (11)

Country Link
US (1) US6642237B1 (enExample)
EP (1) EP1242426B1 (enExample)
JP (1) JP2003514910A (enExample)
AT (1) ATE377011T1 (enExample)
AU (1) AU777824B2 (enExample)
CA (1) CA2391643C (enExample)
CO (1) CO5261497A1 (enExample)
DE (1) DE60036961T2 (enExample)
ES (1) ES2295068T3 (enExample)
PE (1) PE20011025A1 (enExample)
WO (1) WO2001038332A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815567D0 (en) * 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
WO2001055326A2 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US7049146B2 (en) 2000-11-14 2006-05-23 Facet Analytical Services And Technology, Llc Calibration standards, methods, and kits for water determination
US7122376B2 (en) * 2001-11-01 2006-10-17 Facet Analytical Services And Technology, Llc Calibration standards, methods, and kits for water determination
US6649761B2 (en) 2001-05-30 2003-11-18 Merck & Co., Inc. Process for preparing piperazinepentaneamide HIV protease inhibitors
WO2002096359A2 (en) * 2001-05-30 2002-12-05 Merck & Co., Inc. Piperazine pentanamide hiv protease inhibitors
US6835860B2 (en) 2002-02-01 2004-12-28 Merck & Co., Inc. Iodohydroxylation of olefins
US20040067216A1 (en) * 2002-02-22 2004-04-08 Karki Shyam B. Hiv protease inhibitors supported on cation exchange resins for oral administration
GB0218876D0 (en) * 2002-08-13 2002-09-25 Merck Sharp & Dohme Therapeutic agents
AU2003270727A1 (en) * 2002-09-17 2004-04-08 Luna Innovations, Inc. Remote temperature sensing of small volume and related apparatus thereof
US7199240B2 (en) 2002-12-11 2007-04-03 Merck & Co., Inc. Reductive alkylation of saturated cyclic amines
JP4896518B2 (ja) * 2002-12-13 2012-03-14 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド ニコチンアミド系キナーゼ阻害薬
TW574132B (en) * 2003-04-14 2004-02-01 Univ Nat Cheng Kung Integrated microfluidic electro-spray chip system and the analysis method thereof
US7161015B1 (en) * 2005-09-08 2007-01-09 The United States Of America As Represented By The Secretary Of The Navy Method of making 2-furylalkylketones
JP2006316049A (ja) * 2006-04-11 2006-11-24 Tanabe Seiyaku Co Ltd 2,2−ジアルコキシエチルアミン化合物およびその製造方法
JP2012528160A (ja) 2009-05-27 2012-11-12 メルク・シャープ・エンド・ドーム・コーポレイション Hivプロテアーゼ阻害薬
ES2898348T3 (es) 2009-10-26 2022-03-07 Merck Sharp & Dohme Composiciones farmacéuticas sólidas que contienen un inhibidor de la integrasa
CA2794952C (en) 2010-04-01 2018-05-15 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
WO2012052412A1 (de) 2010-10-22 2012-04-26 Bayer Cropscience Ag Neue heterocylische verbindungen als schädlingsbekämpfungsmittel
WO2012055031A1 (en) 2010-10-28 2012-05-03 Merck Canada Inc. Hiv protease inhibitors
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
US9226505B2 (en) 2011-09-23 2016-01-05 Bayer Intellectual Property Gmbh 4-substituted 1-phenylpyrazole-3-carboxylic acid derivatives as agents against abiotic plant stress
EP2771332B1 (en) 2011-10-26 2016-06-29 Merck Canada Inc. Thiophen and thiazol sulfonamid derivatives as HIV protease inhibitors for the treatment of AIDS
BR112015005347A2 (pt) 2012-09-11 2017-08-08 Merck Sharp & Dohme Corp E Merck Canada Inc composto, composição farmacêutica, e, método para tratamento ou profilaxia de infecção por hiv ou para tratamento, profilaxia, ou atraso no início de aids
WO2015013835A1 (en) 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp. Piperazine derivatives as hiv protease inhibitors
EP3052132B1 (en) 2013-09-30 2020-07-29 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
WO2015095265A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Hiv protease inhibitors
WO2015095276A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Hiv protease inhibitors
WO2015134366A1 (en) 2014-03-06 2015-09-11 Merck Sharp & Dohme Corp. Hiv protease inhibitors
US10138255B2 (en) 2014-03-10 2018-11-27 Merck Sharp & Dohme Corp. Piperazine derivatives as HIV protease inhibitors
EP2944955A1 (en) * 2014-05-13 2015-11-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Benchmark for LC-MS systems
MX387903B (es) * 2014-07-08 2025-03-19 Corteva Agriscience Llc Proceso para la preparacion de acidos 3-hidroxipicolinicos.
CN104311479B (zh) * 2014-09-15 2016-06-15 西华大学 3,5-二碘-4-羟基吡啶的合成
US9938265B2 (en) * 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
WO2019175464A1 (en) 2018-03-14 2019-09-19 Orion Corporation Compounds useful as inhibitors of sodium-calcium exchanger (ncx)
AR114422A1 (es) 2018-03-30 2020-09-02 Syngenta Participations Ag Compuestos herbicidas
CN113329629A (zh) 2018-11-12 2021-08-31 先正达农作物保护股份公司 除草化合物
CN112824417A (zh) * 2019-11-21 2021-05-21 上海天慈国际药业有限公司 一种劳拉替尼的制备方法
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8927913D0 (en) 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
CA2081970C (en) 1991-11-08 1997-07-08 Joseph P. Vacca Hiv protease inhibitors useful for the treatment of aids
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
IL110255A (en) 1993-07-16 1998-12-06 Merck & Co Inc Formation and resolution of 2-tert-butylcarboxamido-piperazine
US5455351A (en) * 1993-12-13 1995-10-03 Abbott Laboratories Retroviral protease inhibiting piperazine compounds
HUT74681A (en) 1993-12-15 1997-01-28 Merck & Co Inc N-(2-hydroxy-1-indenyl)-2-phenylmethyl-4-hydroxy-5-(2-carboxamido-piperazinyl)-pentaneamide derivatives of hiv protease inhibitor activity and phrmaceutical compositions contining them
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
TW438799B (en) * 1997-05-29 2001-06-07 Merck & Co Inc HIV protease inhibitor
WO1999033795A1 (en) * 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors

Similar Documents

Publication Publication Date Title
CA2391643A1 (en) Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides as hiv protease inhibitors
JP4966866B2 (ja) mGluR5アンタゴニストとしてのチアゾール−4−カルボキサミド誘導体
TWI246510B (en) Thiazolidine derivatives and pharmaceutical uses thereof
JP6017313B2 (ja) 化合物および方法
JP5412429B2 (ja) 抗細菌性アミド及びスルホンアミド置換複素環式尿素化合物
US7169931B2 (en) Cyclic compounds exhibiting thrombopoietin receptor agonism
JP6013375B2 (ja) キナーゼ阻害剤としてのチアゾリルフェニル−ベンゼンスルホンアミド誘導体
JP4638355B2 (ja) チアゾール誘導体
US10836755B2 (en) Cardiac sarcomere inhibitors
JP4324791B2 (ja) 2−アシルアミノチアゾール誘導体又はその塩
JP2007523905A5 (enExample)
JP2005526814A5 (enExample)
JP2009531309A5 (enExample)
US9045466B2 (en) Amidine compound or salt thereof
IL196129A (en) Human protein tyrosine phosphatase inhibitors, compositions comprising such compounds and uses thereof in the preparation of medicaments for regulating angiogenesis
JP2009524670A5 (enExample)
JPWO2007026761A1 (ja) チアゾール誘導体
JP2016510810A5 (enExample)
US20250136570A1 (en) Hdac inhibitors and therapeutic use thereof
CA2566896A1 (en) Bicyclic-substituted amines having cyclic-substituted monocyclic substituents for modulating effects of histamine-3 receptor
CA2850551A1 (en) Pyridine derivatives
AU2005258397A1 (en) Pyrazole derivatives
JP4774995B2 (ja) アシルアミノチアゾール誘導体を有効成分とする医薬組成物
JP2008503575A5 (enExample)
WO2013031694A1 (ja) アミン化合物またはその塩